Peter Fromen News Today

Product delivers epigenetic information from a single low-input DNA library without medical treatment - News - PharmaTimes

Biomodal (formerly known as Cambridge Epigenetix) commercially launches its new duet multiomics solution, revealing the combinatorial power of genetic and...

Genomics Veteran to Lead Company Which Has a Commercial-Ready Novel Technology Platform that Can Realize the Largely Untapped Contribution of Epigenetics to Human HealthCAMBRIDGE, United Kingdom, June

The automated workflows will use the Robotic Biology Institute's LabDroid to support whole-genome sequencing, targeted sequencing, and RNA isoform sequencing.

Clearwater Capital Advisors LLC boosted its holdings in shares of Pacific Biosciences of California, Inc. (NASDAQ:PACB – Get Rating) by 15.1% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 10,394 shares of the biotechnology company’s stock after buying an […]

Foundations Investment Advisors LLC bought a new stake in Pacific Biosciences of California, Inc. (NASDAQ:PACB – Get Rating) in the fourth quarter, Holdings Channel.com reports. The institutional investor bought 10,688 shares of the biotechnology company’s stock, valued at approximately $154,000. A number of other hedge funds and other institutional investors have also bought and sold […]

StockNews.com upgraded shares of Pacific Biosciences of California (NASDAQ:PACB – Get Rating) to a sell rating in a report published on Tuesday morning. Several other research firms have also issued reports on PACB. Piper Sandler cut their price target on Pacific Biosciences of California from $20.00 to $13.00 in a report on Tuesday, March 1st. […]

Shares of Pacific Biosciences of California, Inc. (NASDAQ:PACB – Get Rating) fell 3.7% on Friday . The company traded as low as $10.32 and last traded at $10.53. 65,616 shares changed hands during trading, a decline of 99% from the average session volume of 4,776,942 shares. The stock had previously closed at $10.93. A number […]

Abacus Planning Group Inc. cut its holdings in shares of Pacific Biosciences of California, Inc. (NASDAQ:PACB – Get Rating) by 13.9% during the fourth quarter, HoldingsChannel.com reports. The firm owned 155,000 shares of the biotechnology company’s stock after selling 25,000 shares during the quarter. Pacific Biosciences of California makes up 0.8% of Abacus Planning Group […]

Operator Thank you for standing by, and welcome to the Pacific Biosciences of California, Inc. fourth-quarter 2020 earnings conference call. [Operator instructions] I would now like to hand the conference over to Trevin Rard. Please go ahead. Trevin Rard -- Investor Relations Thank you. Good afternoon, and welcome to the Pacific Biosciences fourth-quarter 2020 earnings conference call. We hope that youre keeping well during this time. Earlier today, we issued a press release outlining the fina...